查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1625473

去勢抵抗性前列腺癌市場、規模、佔有率、趨勢、行業分析報告（按療法和地區）- 市場預測，2025-2034 年

Castrate-Resistant Prostate Cancer Market Size, Share, Trends, Industry Analysis Report: By Therapy and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，去勢抵抗性前列腺癌 (CRPC) 市場預計到 2034 年將達到 297.9 億美元。該研究報告對當前市場動態提供了詳細的見解，並對未來市場成長進行了分析。

去勢抵抗性前列腺癌市場的成長是由發病率的上升所推動的，尤其是在老齡化人口中。前列腺癌通常會發展到較晚期、難以治療的階段。這促使對有效治療的需求增加，從而推動了標靶治療和精準腫瘤學的進步。賽諾菲公司、強生公司、輝瑞公司、拜耳公司和安斯泰來製藥公司等主要參與者正在透過先進的產品和持續的創新來推動這個市場。隨著主要參與者專注於雄激素受體抑制劑、免疫療法和其他有針對性的方法等新型治療方法，CRPC 市場規模正在擴大。這些進步正在幫助提供全面 CRPC 治療方案的公司獲得市場佔有率。

去勢抵抗性前列腺癌的市場趨勢表明，人們正轉向個人化醫療和聯合療法，以提供更高的療效和更少的副作用。北美憑藉其強大的醫療保健基礎設施、高度的知名度和成熟的醫學研究機構在全球市場佔據主導地位。然而，由於前列腺癌盛行率上升、醫療保健機會改善和監管對新療法的支持，預計亞太地區將呈現最高的複合年增長率。這些地區去勢抵抗性前列腺癌 (CRPC) 市場的成長反映了全球對腫瘤學研究和治療的投資不斷增加的廣泛趨勢。此外，隨著各公司尋求擴大其產品線和地理覆蓋範圍，合作和併購活動也十分活躍，進一步推動了去勢抵抗性前列腺癌市場的擴張。

去勢抵抗性前列腺癌市場報告重點

由於荷爾蒙療法透過降低雄性激素水平來減緩病情進展的有效性已被證實，因此荷爾蒙療法領域將在 2024 年佔據去勢抵抗性前列腺癌市場的最大佔有率。

預計免疫治療領域在預測期內的複合年增長率將達到1.5%，因為它提供了一種有前景且侵入性較小的治療選擇，能夠利用人體的免疫系統專門針對和攻擊前列腺癌細胞。

由於其先進的醫療保健基礎設施和前列腺癌的高盛行率，北美在 2024 年佔據了去勢抵抗性前列腺癌市場的主導佔有率。

由於人們對先進治療方案的認識不斷提高以及政府在癌症治療方面的支持措施，預計亞太市場在預測期內將出現顯著增長。

全球市場的主要參與者是賽諾菲公司、強生公司、輝瑞公司、拜耳公司、雅培實驗室、葛蘭素史克公司、西北生物治療公司、Active Biotech AB、安斯泰來製藥公司和Dendreon 公司。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章 研究方法

第 4 章全球去勢抵抗性前列腺癌市場洞察
  • 市場概況
  • 去勢抵抗性前列腺癌市場動態
    • 推動因素和機遇
      • 攝護腺癌發生率不斷上升
      • 老年人口增加
    • 阻礙因素和課題
      • 末期病患的治療選擇有限
  • PESTEL 分析
  • 去勢抵抗性攝護腺癌的市場趨勢
  • 價值鏈分析
  • COVID-19 影響分析

第5章 全球去勢抵抗性前列腺癌市場（依療法劃分）

  • 主要發現
  • 簡介
  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 放射治療

第6章全球去勢抗性前列腺癌市場（按地區）

  • 主要發現
  • 簡介
      去勢抵抗性前列腺癌市場評估：地區，2020 年至 2034 年
  • 北美洲
    • 北美，依療法分類，2020 年至 2034 年
    • 美國
    • 加拿大
  • 歐洲
      歐洲：依療法分類，2020 年至 2034 年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲國家
    亞太地區
      亞太地區，依療法分類，2020 年至 2034 年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲
    • 中東和非洲：依療法分類，2020 年至 2034 年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲地區
  • 拉丁美洲
    • 拉丁美洲，依療法分類，2020 年至 2034 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家

第 7 章 競爭格局

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協定/揭露

第 8 章 公司簡介

  • Sanofi S.A.
  • Johnson & Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Corporation
Product Code: PM5332

The castrate-resistant prostate cancer (CRPC) market size is expected to reach USD 29.79 billion by 2034, according to a new study by Polaris Market Research. The report "Castrate-Resistant Prostate Cancer Market Share, Size, Trends, Industry Analysis Report: By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The castrate-resistant prostate cancer market growth is attributed to increasing incidence rates, especially among aging populations. Prostate cancer often progresses to a more advanced, treatment-resistant stage. Thus, the demand for effective therapies has grown, leading to advancements in targeted treatments and precision oncology. Key players such as Sanofi S.A.; Johnson & Johnson; Pfizer, Inc.; Bayer AG; and Astellas Pharma, Inc. drive this market with leading products and continued innovation. The CRPC market size has expanded as major companies focus on novel therapies such as androgen receptor inhibitors, immunotherapies, and other targeted approaches. Such advancements have contributed to increased market share among companies offering comprehensive CRPC treatment options.

The castrate-resistant prostate cancer market trends indicate a shift toward personalized medicine and combination therapies that offer enhanced efficacy with fewer side effects. North America dominates the global market due to robust healthcare infrastructure, high awareness, and established medical research institutions. However, Asia Pacific is expected to witness the highest CAGR due to rising prostate cancer incidence, improved healthcare access, and regulatory support for new treatments. The castrate-resistant prostate cancer market (CRPC) market growth in these regions reflects a broader global trend of increasing investments in oncology research and treatment. Additionally, partnerships, and mergers and acquisitions are prevalent, as companies seek to expand their product pipelines and geographic reach, further fueling the castrate-resistant prostate cancer market expansion.

Castrate-Resistant Prostate Cancer Market Report Highlights

In terms of therapy, in 2024, the hormonal therapy segment accounted for the largest share of the castrate-resistant prostate cancer market due to its proven effectiveness in slowing disease progression by reducing androgen levels.

The immunotherapy segment is expected to witness the highest CAGR during the forecast period due to its ability to harness the body's immune system to specifically target and attack prostate cancer cells, offering a promising and less invasive treatment option.

In 2024, North America dominated the castrate-resistant prostate cancer market share due to its advanced healthcare infrastructure and high prevalence of prostate cancer.

The Asia Pacific market is expected to witness significant growth during the forecast period due to the growing awareness of advanced treatment options and supportive government initiatives in cancer care.

A few global key market players are Sanofi S.A.; Johnson and Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc; and Dendreon Corporation.

Polaris Market Research has segmented the castrate-resistant prostate cancer market report on the basis of therapy, and region:

By Therapy Outlook (Revenue, USD Billion; 2020-2034)

  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiotherapy

By Regional Outlook (Revenue, USD Billion; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Castrate-resistant Prostate Cancer Market Insights

  • 4.1. Castrate-resistant Prostate Cancer Market - Market Snapshot
  • 4.2. Castrate-resistant Prostate Cancer Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Prostate Cancer
      • 4.2.1.2. Growing Geriatric Population
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Treatment Options for Late-stage Disease
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Castrate-resistant Prostate Cancer Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Castrate-resistant Prostate Cancer Market, by Therapy

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Castrate-resistant Prostate Cancer Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 5.4. Hormonal Therapy
    • 5.4.1. Global Castrate-resistant Prostate Cancer Market, by Hormonal Therapy, by Region, 2020-2034 (USD Billion)
  • 5.5. Immunotherapy
    • 5.5.1. Global Castrate-resistant Prostate Cancer Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 5.6. Radiotherapy
    • 5.6.1. Global Castrate-resistant Prostate Cancer Market, by Radiotherapy, by Region, 2020-2034 (USD Billion)

6. Global Castrate-resistant Prostate Cancer Market, by Geography

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Castrate-resistant Prostate Cancer Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 6.3. Castrate-resistant Prostate Cancer Market - North America
    • 6.3.1. North America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.3.2. Castrate-resistant Prostate Cancer Market - U.S.
      • 6.3.2.1. U.S.: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.3.3. Castrate-resistant Prostate Cancer Market - Canada
      • 6.3.3.1. Canada: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4. Castrate-resistant Prostate Cancer Market - Europe
    • 6.4.1. Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.2. Castrate-resistant Prostate Cancer Market - UK
      • 6.4.2.1. UK: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.3. Castrate-resistant Prostate Cancer Market - France
      • 6.4.3.1. France: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.4. Castrate-resistant Prostate Cancer Market - Germany
      • 6.4.4.1. Germany: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.5. Castrate-resistant Prostate Cancer Market - Italy
      • 6.4.5.1. Italy: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.6. Castrate-resistant Prostate Cancer Market - Spain
      • 6.4.6.1. Spain: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.7. Castrate-resistant Prostate Cancer Market - Netherlands
      • 6.4.7.1. Netherlands: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.8. Castrate-resistant Prostate Cancer Market - Russia
      • 6.4.8.1. Russia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.9. Castrate-resistant Prostate Cancer Market - Rest of Europe
      • 6.4.9.1. Rest of Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5. Castrate-resistant Prostate Cancer Market - Asia Pacific
    • 6.5.1. Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.2. Castrate-resistant Prostate Cancer Market - China
      • 6.5.2.1. China: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.3. Castrate-resistant Prostate Cancer Market - India
      • 6.5.3.1. India: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.4. Castrate-resistant Prostate Cancer Market - Malaysia
      • 6.5.4.1. Malaysia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.5. Castrate-resistant Prostate Cancer Market - Japan
      • 6.5.5.1. Japan: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.6. Castrate-resistant Prostate Cancer Market - Indonesia
      • 6.5.6.1. Indonesia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.7. Castrate-resistant Prostate Cancer Market - South Korea
      • 6.5.7.1. South Korea: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.8. Castrate-resistant Prostate Cancer Market - Australia
      • 6.5.8.1. Australia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.9. Castrate-resistant Prostate Cancer Market - Rest of Asia Pacific
      • 6.5.9.1. Rest of Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6. Castrate-resistant Prostate Cancer Market - Middle East & Africa
    • 6.6.1. Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.2. Castrate-resistant Prostate Cancer Market - Saudi Arabia
      • 6.6.2.1. Saudi Arabia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.3. Castrate-resistant Prostate Cancer Market - UAE
      • 6.6.3.1. UAE: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.4. Castrate-resistant Prostate Cancer Market - Israel
      • 6.6.4.1. Israel: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.5. Castrate-resistant Prostate Cancer Market - South Africa
      • 6.6.5.1. South Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.6. Castrate-resistant Prostate Cancer Market - Rest of Middle East & Africa
      • 6.6.6.1. Rest of Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.7. Castrate-resistant Prostate Cancer Market - Latin America
    • 6.7.1. Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.2. Castrate-resistant Prostate Cancer Market - Mexico
      • 6.7.2.1. Mexico: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.3. Castrate-resistant Prostate Cancer Market - Brazil
      • 6.7.3.1. Brazil: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.4. Castrate-resistant Prostate Cancer Market - Argentina
      • 6.7.4.1. Argentina: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.5. Castrate-resistant Prostate Cancer Market - Rest of Latin America
      • 6.7.5.1. Rest of Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

7. Competitive Landscape

  • 7.1. Expansion and Acquisition Analysis
    • 7.1.1. Expansion
    • 7.1.2. Acquisitions
  • 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8. Company Profiles

  • 8.1. Sanofi S.A.
    • 8.1.1. Company Overview
    • 8.1.2. Financial Performance
    • 8.1.3. Product Benchmarking
    • 8.1.4. Recent Development
  • 8.2. Johnson & Johnson
    • 8.2.1. Company Overview
    • 8.2.2. Financial Performance
    • 8.2.3. Product Benchmarking
    • 8.2.4. Recent Development
  • 8.3. Pfizer, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Financial Performance
    • 8.3.3. Product Benchmarking
    • 8.3.4. Recent Development
  • 8.4. Bayer AG
    • 8.4.1. Company Overview
    • 8.4.2. Financial Performance
    • 8.4.3. Product Benchmarking
    • 8.4.4. Recent Development
  • 8.5. Abbott Laboratories
    • 8.5.1. Company Overview
    • 8.5.2. Financial Performance
    • 8.5.3. Product Benchmarking
    • 8.5.4. Recent Development
  • 8.6. GlaxoSmithKline PLC
    • 8.6.1. Company Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Product Benchmarking
    • 8.6.4. Recent Development
  • 8.7. Northwest Biotherapeutics, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Performance
    • 8.7.3. Product Benchmarking
    • 8.7.4. Recent Development
  • 8.8. Active Biotech AB
    • 8.8.1. Company Overview
    • 8.8.2. Financial Performance
    • 8.8.3. Product Benchmarking
    • 8.8.4. Recent Development
  • 8.9. Astellas Pharma, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Product Benchmarking
    • 8.9.4. Recent Development
  • 8.10. Dendreon Corporation
    • 8.10.1. Company Overview
    • 8.10.2. Financial Performance
    • 8.10.3. Product Benchmarking
    • 8.10.4. Recent Development

List of Tables:

Table 1 Global Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 2 North America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 3 U.S.: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 4 Canada: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 5 Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 6 UK: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 7 France: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 8 Germany: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 9 Italy: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 10 Spain: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 11 Netherlands: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 12 Russia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 13 Rest of Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 14 Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 15 China: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 16 India: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 17 Malaysia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 18 Japan: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 19 Indonesia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 20 South Korea: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 21 Australia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 22 Rest of Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 23 Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 24 Saudi Arabia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 25 UAE: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 26 Israel: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 27 South Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 28 Rest of Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 29 Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 30 Mexico: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 31 Brazil: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 32 Argentina: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 33 Rest of Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

List of Figures:

Figure 1. Global Castrate-resistant Prostate Cancer Market, 2020-2034 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Therapy

Figure 7. Global Castrate-resistant Prostate Cancer Market, by Therapy, 2024 & 2034 (USD Billion)